GR

Green Cross Holdings

A biotech firm in biopharma, diagnostics, digital health, and consumer wellness products.

005250 | KO

Overview

Corporate Details

ISIN(s):
KR7005250006
LEI:
Country:
South Korea
Address:
경기 용인시 구성읍 동백리 (주)녹십자 303, 용인시
Sector:
Manufacturing
Industry:
Manufacture of pharmaceuticals, medicinal chemical and botanical products

Description

Green Cross Holdings is a holding company focused on the healthcare and biotechnology industries. Its core operations are divided into four main segments: Biopharma & Innovative Technology, Diagnosis, Digital Healthcare, and Consumer Health. The Biopharma division is a key area, specializing in the development, manufacturing, and marketing of plasma derivatives, protein therapeutics, and vaccines. The company is recognized for developing the world's first pandemic hemorrhagic fever vaccine and South Korea's first flu vaccine. The Diagnosis segment provides in-vitro diagnostic services and supports clinical trials. Its Digital Healthcare platform facilitates remote medical services and monitoring, while the Consumer Health division offers functional foods and wellness products. The company maintains a global presence, exporting its products to numerous countries.

Unlock This Filing & Millions More

You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.

Filings

You have of free filing views remaining. Upgrade for unlimited access.
Quick Filters:

Filters

Clear
Bulk Actions:
Date Filing Language Size Actions
2025-08-29 00:00
Major Shareholding Notification
주식등의대량보유상황보고서(일반)
Korean 212.2 KB
2025-08-14 00:00
Interim Report
반기보고서 (2025.06)
Korean 4.6 MB
2025-06-26 00:00
Prospectus
투자설명서
Korean 4.8 MB
2025-06-26 00:00
Share Issue/Capital Change
증권발행실적보고서
Korean 54.8 KB
2025-06-25 00:00
Registration Form
[발행조건확정]증권신고서(채무증권)
Korean 15.4 KB
2025-06-20 00:00
Prospectus
[기재정정]증권신고서(채무증권)
Korean 5.5 MB
2025-06-20 00:00
Registration Form
[발행조건확정]증권신고서(채무증권)
Korean 612.7 KB
2025-06-19 00:00
M&A Activity
타법인주식및출자증권취득결정
Korean 18.1 KB
2025-06-16 00:00
Registration Form
증권신고서(채무증권)
Korean 4.7 MB
2025-06-02 00:00
Governance Information
기업지배구조보고서공시
Korean 852.3 KB
2025-05-15 00:00
Quarterly Report
분기보고서 (2025.03)
Korean 3.9 MB
2025-04-25 00:00
Major Shareholding Notification
임원ㆍ주요주주특정증권등소유상황보고서
Korean 29.3 KB
2025-04-25 00:00
Major Shareholding Notification
최대주주등소유주식변동신고서
Korean 92.4 KB
2025-04-11 00:00
Major Shareholding Notification
주식등의대량보유상황보고서(일반)
Korean 258.1 KB
2025-04-11 00:00
Major Shareholding Notification
최대주주등소유주식변동신고서
Korean 83.3 KB

Automate Your Workflow. Get a real-time feed of all Green Cross Holdings filings delivered via API.

Explore Data Feeds →

Market Data

Market Data Not Available

Financials & KPIs

No data available

Unlock Full Financials for Green Cross Holdings

This data is available as part of our premium data solutions. Contact our team for access.

Need More History? Access decades of standardized financials for Green Cross Holdings via our API.

Get Historical Data →

Insider Transactions

Date Insider Name Position Type Shares Value
No insider transactions recorded for this company.

Peer Companies

Elicera Therapeutics AB Logo
Develops CAR T-cell & oncolytic virus therapies for cancer, enhanced by its iTANK platform.
Sweden
ELIC
ELI LILLY & Co Logo
Pharma leader developing medicines for diabetes, obesity, oncology, and neuroscience.
United States of America
LLY
Ellen AB Logo
Develops research-based probiotic and prebiotic products for women's intimate health and pH balance.
Sweden
ELN
ELUTIA INC. Logo
Develops drug-eluting biologics to reduce complications from medical implants.
United States of America
ELUT
Emergent BioSolutions Inc. Logo
Develops and manufactures medical countermeasures for public health and national security threats.
United States of America
EBS
ENANTA PHARMACEUTICALS INC Logo
Developing novel small molecule drugs for virology (HCV, RSV) and immunological diseases.
United States of America
ENTA
enGene Holdings Inc. Logo
Developing non-viral, locally administered gene therapies for rare genetic conditions.
United States of America
ENGN
Enliven Therapeutics, Inc. Logo
A clinical-stage biopharma developing kinase inhibitors for precision oncology cancer treatment.
United States of America
ELVN
Enlivex Therapeutics Ltd. Logo
Developing cell therapy that reprograms macrophages to treat immune hyper-responses like sepsis.
United States of America
ENLV
Enlivex Therapeutics Ltd. Logo
Developing cell therapy to restore immune balance for inflammatory diseases like sepsis.
Israel
ENLV

Talk to a Data Expert

Have a question? We'll get back to you promptly.